Announcements Trials
Browse Landscape

Phase

Phase 3 7Phase 2 4Phase NA 3Phase 1/2 3Phase 4 1Phase 2/3 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 15Other hematologic neoplasm 13Plasma cell 8Thoracic 3Head & Neck 1Gynecologic 1CNS 1Breast 1

Conditions

Vomiting 1Uterine Cervical Neoplasms 1

Interventions

Paclitaxel 12Carboplatin 11Cisplatin 9Letrozole 6Drug Therapy 6liposomal doxorubicin 5Megestrol Acetate 4Bevacizumab 4spartalizumab 3Topotecan 3Taxes 3Medroxyprogesterone Acetate 3olaparib 2niraparib 2atezolizumab 2Methotrexate 2Magnetic Resonance Spectroscopy 2Imiquimod 2Hyperthermic Intraperitoneal Chemotherapy 2Gonadotropin-Releasing Hormone 2Gemcitabine 2Doxorubicin 21-dodecylpyridoxal 2trametinib 1sintilimab 1saracatinib 1ricin A-GnRH conjugate 1pertuzumab 1pembrolizumab 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Dexamethasone × Gynecologic × Clear all
NCT03668639 2021-12-14

Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin

Odense University Hospital

Phase 2/3 Unknown
80 enrolled
Gynecologic

Uterine Cervical Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡